Cholangiocarcinoma: the quest for a second-line systemic treatment.
Ontology highlight
ABSTRACT: Biliary tract cancers (BTC) are a heterogeneous group of epithelial neoplasms, with a poor prognosis. Advanced BTC remains a challenging, non-curable disease. Gemcitabine plus platinum chemotherapy is the standard of care as first-line (L1) therapy in this setting. Beyond failure of L1, available evidence to guide therapeutic decisions is scarce. Data from phase III studies are lacking and there is no validated strategy to date. In this review, we provide an overview of the systemic therapeutic options that can be proposed and unsolved questions in the management of patients with advanced BTC in the second-line (L2) setting. Criteria to select which patients should receive L2 therapy are ill defined and reliable prognostic tools and models to help estimate individual patient survival at th
SUBMITTER: Vienot A
PROVIDER: S-EPMC8797902 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA